← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Biochip Labs, Inc.
Cleveland, OH
$5,737,428
Total funding
5
Grants
Funding over time
peak $2M · FY2021–25$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,395,940 · 3
NSF$1,341,488 · 2
By mechanism
R42$4,395,940 · 3
—$1,341,488 · 2
Investigators at Biochip Labs, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
STTR Phase II: Optimized manufacturing and machine learning based automation of Endothelium-on-a-chip microfluidic devices for drug screening applications.$1,085,488
· FY2024 · TIP
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability$865,376
R42 · FY2023 · HL
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability$865,375
R42 · FY2024 · HL
Endothelialized microfluidic assays for emerging therapies in sickle cell disease$852,121
R42 · FY2022 · HL
Endothelialized microfluidic assays for emerging therapies in sickle cell disease$842,828
R42 · FY2023 · HL
Manufacturing and Analytical Validation of the Microfluidic Impedance Red Cell Assay (MIRCA) for Commercial Viability$312,371
R42 · FY2025 · HL
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability$259,611
R42 · FY2022 · HL
Endothelialized microfluidic assays for emerging therapies in sickle cell disease$256,578
R42 · FY2021 · HL
STTR Phase I: Standardized and reproducible culture and activation of endothelial cells in microfluidic devices for drug screening applications$256,000
· FY2021 · TIP
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability (Administrative Supplement)$70,840
R42 · FY2024 · HL
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability$70,840
R42 · FY2023 · HL